AGENT – The US Food and Drug Administration (FDA) announced yesterday (May 5) that it will limit the emergency approval of Johnson & Johnson’s COVID-19 vaccine in the United States. It also allows for vaccination in those who are concerned about mRNA vaccine side effects, and those vaccinated with J&J will be deemed to have received the full dose of the COVID-19 vaccine.
US media CNN reported yesterday (May 5) that the US Food and Drug Administration said in a statement on Thursday that changes in the vaccine’s emergency permitting Johnson & Johnson, or J&J, in the United States due to the risk of serious, rare diseases. Thrombosis with thrombocytopenia (Thrombocytopenia syndrome or TTS) after receiving this type of vaccine.
“We have been closely monitoring Janssen’s COVID-19 vaccine and TTS post-vaccination conditions and have used updated information from our security surveillance system to determine the extent of TTS. Improve the EUA,” Dr. Peter Marks, Director of the FDA Center for Biologics Evaluation and Research.”
However, in a statement, the FDA confirmed it would continue to allow the J&J vaccine to continue in the United States, stating: “We recognize that Janssen’s COVID-19 vaccine continues to play a role in responding to the current pandemic crisis. In the U.S. and across the global community…what comes out today demonstrates the strength of our surveillance systems and our commitment to ensuring science and data guide action. ours.”
The J&J vaccine will continue to ensure that it is fully vaccinated against COVID-19 for those who have received it and will not be considered immune to the COVID-19 vaccine for those who have not received the J&J vaccine or the mRNA vaccine. It was also given to people who did not have access to the mRNA vaccine, or to people with personal concerns about the side effects of the mRNA vaccine, and to those who had allergic reactions to the mRNA vaccine, including both the Pfizer- Biotech and Moderna Vaccines
The FDA confirmed to CNN that the revised authorization for the J&J vaccine will also apply to the booster vaccine. The US Food and Drug Administration said We assessed the benefits of the vaccine to outweigh the risks in certain groups of the population.
Figures on Thursday showed that more than 18.7 million doses of the J&J vaccine have been distributed to the US public. And of the total number of people vaccinated with full doses of the COVID-19 vaccine, around 7.7% received the J&J vaccine.